malaria · reviewed 2026-08-01
Artesunate and Qing Hao: a Chinese discovery lineage that depends on exact formulation
Qing Hao led to artemisinin, and artemisinin led to semisynthetic artesunate. The lineage is direct and profound; raw Artemisia material is still not equivalent to quality-assured artesunate or combination malaria treatment.
Defined medicine
artesunate
artesunic acid derivative · intravenous artesunate
Where it came from
Artesunate is a semisynthetic derivative made from dihydroartemisinin, itself derived from artemisinin discovered in Qing Hao. Artemisinin supply can begin with Artemisia annua or an engineered-yeast artemisinic-acid route followed by chemistry. nobel-tu artesunate-label yeast-artemisinin
What it is trying to achieve
Intravenous artesunate is a rapidly acting treatment for severe malaria. In a large African trial, artesunate reduced mortality compared with quinine; complete malaria care still depends on the parasite, severity, partner treatment, and resistance setting. artesunate-label aquamat who-malaria
How it acts
Artesunate is rapidly converted to active dihydroartemisinin, and its endoperoxide group is essential to antimalarial activity. Downstream molecular targets and their relative contributions remain incompletely resolved rather than one settled mechanism. artesunate-label who-malaria
Why people developed this form
Chemical derivatisation pursued a rapidly available, water-compatible artemisinin medicine suitable for severe malaria, while combination regimens were developed to clear infection and slow selection of resistance. artesunate-label who-malaria
Present form and manufacture
The cited product is sterile artesunate for injection with a specified reconstitution system and quality standard. It is clinically distinct from oral artemisinin monotherapy, plant powder, capsules, tea, or juice. artesunate-label who-artemisia
Bioavailability
Intravenous delivery gives controlled systemic artesunate exposure followed by rapid conversion to dihydroartemisinin. Plant artemisinin concentration and oral absorption vary, so leaf content cannot predict equivalent parasite exposure. artesunate-label who-artemisia
Its own risks
Serious malaria itself is immediately dangerous. Labelled artesunate risks include hypersensitivity and post-treatment haemolysis, while incomplete or subtherapeutic artemisinin exposure can contribute to failure and resistance. artesunate-label who-artemisia who-malaria
What nature offers
No link below is assumed to be equivalent. Each names the organism or tradition, exact preparation, measured exposure, human evidence, and replacement boundary separately.
Nature link · Historical discovery lead
Qing Hao
Artemisia annua
青蒿 · sweet wormwood · annual wormwood
- Exact material
- Authenticated Artemisia annua aerial material and isolated pharmaceutical artemisinin are distinct; plant teas, powders, juices, extracts, and cultivars are not pooled. nobel-tu who-artemisia
- Relationship
- Historical discovery lead. Observation of a natural material or molecule helped reveal the drug family, without making the final medicine identical to the source.
Lineage
Chinese medical literature served as a historical discovery lead: Tu Youyou's team revisited extraction conditions, isolated qinghaosu or artemisinin, and established the natural molecule from which modern derivatives including artesunate descend. nobel-tu
Traditional context
Qing Hao is a Chinese materia medica with its own historical indications, processing, and formula context. The discovery honoured a textual and practical clue, but modern severe-malaria diagnosis and pharmaceutical dosing are not identical to that tradition. nobel-tu nccih-tcm
Human evidence
Not established or conflicting Evidence product match: no
WHO does not support non-pharmaceutical Artemisia plant material for malaria prevention or treatment because content, exposure, effectiveness, safety, and resistance protection are inadequate or unpredictable. who-artemisia who-malaria
Bioavailability and preparation
Artemisinin concentration differs across genetics, harvest, storage, and preparation, and oral delivery from plant material does not reproduce the labelled intravenous artesunate profile. More plant material is not a validated solution to this variability. who-artemisia ema-herbal-biopharm artesunate-label
Safety
The central danger is a product with uncertain artemisinin exposure being used against a rapidly lethal infection, risking treatment failure, delayed effective care, recrudescence, and selection pressure for resistance. who-artemisia who-malaria
Can it replace the medicine?
Qing Hao plant products are not evidence-equivalent substitutes for quality-assured artesunate or WHO-recommended artemisinin-based combination treatment. who-artemisia who-malaria artesunate-label
The honest comparison
The cited history credits Ge Hong's Handbook of Prescriptions for Emergencies, Tu Youyou and her Project 523 group at the Institute of Chinese Materia Medica, and collaborating Chinese institutes; later trials, formulation, and combination therapy are separate steps. nobel-tu aquamat who-malaria
Qing Hao is the intellectual and biological root; artemisinin is the isolated natural molecule; artesunate is a purpose-built derivative. Respecting that chain means preserving every link and refusing to collapse them into one product. nobel-tu artesunate-label who-artemisia
Sources for this card
- Tu Youyou — biographical account of the Qing Hao discovery path Nobel Prize · official history · read 2026-08-01
- Artesunate for injection prescribing information US Food and Drug Administration · regulatory label · read 2026-08-01
- High-level semi-synthetic production of the potent antimalarial artemisinin Nature · primary research · read 2026-08-01
- African Quinine Artesunate Malaria Trial The Lancet trial archive · primary research · read 2026-08-01
- WHO guidelines for malaria World Health Organization · official guidance · read 2026-08-01
- The use of non-pharmaceutical forms of Artemisia World Health Organization · official guidance · read 2026-08-01
- Traditional Chinese Medicine: What You Need To Know US National Center for Complementary and Integrative Health · official guidance · read 2026-08-01
- Points to consider on the biopharmaceutical characterisation of herbal medicinal products European Medicines Agency · official guidance · read 2026-08-01
Same card as data: /api/remedies/artesunate-qing-hao.json. Found a source or claim problem? Open a correction.